Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended June 30, 2013. The registrant is an Australian biotechnology entity reporting under Rule 12g3-2(b). The filing includes Appendix 4C, a quarterly report for entities admitted on the basis of commitments.
Key Financial Metrics
| Metric | Current Quarter ($A'000) | Year to Date ($A'000) |
|---|---|---|
| Receipts from Customers | 0 | 0 |
| Net Operating Cash Flows | (2,955) | (8,058) |
| Net Investing Cash Flows | (11) | (27) |
| Net Financing Cash Flows | 6,815 | 15,536 |
| Net Increase in Cash | 3,849 | 7,451 |
| Cash at End of Period | 13,347 | 13,347 |
| Proceeds from Share Issues | 7,321 | 16,142 |
| Capital Raising Costs | (506) | (943) |
Debt and Liquidity: The company reported no borrowings, no repayments of borrowings, and no loan facilities or credit standby arrangements used during the period. Liquidity is supported entirely by cash on hand and at bank.
Material Changes
- Revenue: The company generated zero receipts from customers for both the current quarter and the year-to-date period, consistent with a pre-revenue biotechnology development stage.
- Financing: Significant cash inflows were generated through the issuance of shares and options ($7.3 million in the quarter), offsetting operating losses.
- Operating Costs: Research and development expenses were the primary operating outflow, totaling $2.3 million for the quarter and $7.7 million year-to-date.
Outlook, Risks, and Unusual Items
Management Commentary: The filing does not contain narrative management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure requirements of Appendix 4C.
Unusual Items:
- Non-Cash Transactions: During the period, 1,683,791 unlisted options were issued to employees and consultants under the Employee Incentive Scheme and Consulting Agreements.
- Related Party Payments: Aggregate payments to directors and associates totaled $135,000 for the quarter, described as salaries, directors' fees, and consulting fees at normal commercial rates.
Investor Verification Checklist
- Verify the company's current ticker symbol and name status, as the metadata lists "Altery Therapeutics Ltd" while the filing is signed by "Prana Biotechnology Limited."
- Confirm the status of the 1,683,791 unlisted options issued to employees and consultants.
- Review the specific milestones for the $7.7 million in year-to-date R&D spending to assess development progress.
- Validate the cash runway based on the $13.3 million cash balance against the quarterly burn rate of approximately $2.9 million.